

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 DEC 08 INPADOC: Legal Status data reloaded
NEWS 5 SEP 29 DISSABS now available on STN
NEWS 6 OCT 10 PCTFULL: Two new display fields added
NEWS 7 OCT 21 BIOSIS file reloaded and enhanced
NEWS 8 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9 NOV 24 MSDS-CCOHS file reloaded
NEWS 10 DEC 08 CABA reloaded with left truncation
NEWS 11 DEC 08 IMS file names changed
NEWS 12 DEC 09 Experimental property data collected by CAS now available
in REGISTRY
NEWS 13 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS 14 DEC 17 DGENE: Two new display fields added
NEWS 15 DEC 18 BIOTECHNO no longer updated
NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer
available
NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS
databases
NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19 DEC 22 ABI-INFORM now available on STN
NEWS 20 JAN 27 Source of Registration (SR) information in REGISTRY updated
and searchable
NEWS 21 JAN 27 A new search aid, the Company Name Thesaurus, available in
CA/CAPLUS

NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, biosis, COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 17:28:55 ON 30 JAN 2004

FILE 'USPATFULL' ENTERED AT 17:28:55 ON 30 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 17:28:55 ON 30 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 17:28:55 ON 30 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:28:55 ON 30 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 17:28:55 ON 30 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'BIOSIS' ENTERED AT 17:28:55 ON 30 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

=> s GLP-1
5 FILES SEARCHED...
L1 7447 GLP-1

=> s l1 and analog.
L2 514 L1 AND ANALOG

=> s l2 and (7-34)
L3 61 L2 AND (7-34)

=> s l3 and tonicity modifier
L4 1 L3 AND TONICITY MODIFIER

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 1 USPATFULL on STN
TI Peptide pharmaceutical formulations
AB A pharmaceutical composition for administration to a mammal is disclosed. The composition includes a therapeutically effective amount of a peptide, such as a GLP-1 molecule, a PTH molecule, or a GRF molecule. The composition further includes a buffer including a weak acid having an acid dissociation constant value of greater than about 1×10^{-5} , such as acetic acid. The composition also includes an excipient for making the composition generally isotonic, such as D-mannitol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:119850 USPATFULL
TITLE: Peptide pharmaceutical formulations
INVENTOR(S): Holmquist, Barton, Lincoln, NE, UNITED STATES
Dormady, Daniel C., Omaha, NE, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061838	A1	20020523
APPLICATION INFO.:	US 2001-858880	A1	20010517 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205377P	20000517 (60)
	US 2000-205262P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Beth A. Burrous, FOLEY & LARDNER, Suite 500, 3000 K Street, N.W., Washington, DC, 20007-5109	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	929	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 17:28:55 ON 30 JAN 2004

L1 7447 S GLP-1
 L2 514 S L1 AND ANALOG
 L3 61 S L2 AND (7-34)
 L4 1 S L3 AND TONICITY MODIFIER

=> s l3 and solution
 L5 61 L3 AND SOLUTION

=> s l5 and (7-35)
 L6 52 L5 AND (7-35)

=> s l6 and (7-37)
 L7 48 L6 AND (7-37)

=> s l7 and (7-36)
 L8 48 L7 AND (7-36)

=> s l8 and pH
 L9 48 L8 AND PH

=> s l8 and basic pH
 L10 4 L8 AND BASIC PH

=> d l10 ti abs ibib tot

L10 ANSWER 1 OF 4 USPATFULL on STN
 TI Indole carboxylic acids as thyroid receptor ligands
 AB A compound of the formula ##STR1##

wherein W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.13 are as defined herein, useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:113548 USPATFULL
 TITLE: Indole carboxylic acids as thyroid receptor ligands
 INVENTOR(S): Aspnes, Gary E., Rockville, RI, UNITED STATES
 Chiang, Yuan-Ching P., East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078289	A1	20030424
APPLICATION INFO.:	US 2002-255180	A1	20020924 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-325385P	20010926 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3688	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 4 USPATFULL on STN

TI Process for solubilizing glucagon-like peptide 1 compounds
 AB Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution. The GLP-1 solution is then neutralized to a pH at which substantially no amino acid racemization of the GLP-1 compounds occurs, after which the soluble GLP-1 compound is isolated from the neutralized solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:86804 USPATFULL
 TITLE: Process for solubilizing glucagon-like peptide 1 compounds
 INVENTOR(S): Prouty, Walter Francis, JR., Indianapolis, IN, UNITED STATES
 Rinella, Joseph Vincent, JR., Ypsilanti, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060412	A1	20030327
APPLICATION INFO.:	US 2002-169657	A1	20020628 (10)
	WO 2001-US10		20010116
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1103		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 4 USPATFULL on STN

TI Glucagon-like peptide-1 crystals
 AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL
TITLE: Glucagon-like peptide-1 crystals
INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED STATES
Hoffmann, James Arthur, Greenwood, IN, UNITED STATES
Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045464	A1	20030306
	US 6555521	B2	20030429
APPLICATION INFO.:	US 2001-997792	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-209799, filed on 11 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69728P	19971216 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1128	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L10 ANSWER 4 OF 4 USPATFULL on STN

TI GLUCAGON-LIKE PEPTIDE-1 CRYSTALS

AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:134217 USPATFULL
TITLE: GLUCAGON-LIKE PEPTIDE-1 CRYSTALS
INVENTOR(S): HERMELING, RONALD NORBERT, INDIANAPOLIS, IN, United States
HOFFMANN, JAMES ARTHUR, GREENWOOD, IN, United States
NARASIMHAN, CHAKAVARTHY, CARMEL, IN, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014666	A1	20010816
	US 6380357	B2	20020430
APPLICATION INFO.:	US 1998-209799	A1	19981211 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBERT A CONRAD, ELI LILLY AND COMPANY, PATENT DIVISION/RSM, LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1106		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT

17:28:55 ON 30 JAN 2004

L1 7447 S GLP-1
L2 514 S L1 AND ANALOG
L3 61 S L2 AND (7-34)
L4 1 S L3 AND TONICITY MODIFIER
L5 61 S L3 AND SOLUTION
L6 52 S L5 AND (7-35)
L7 48 S L6 AND (7-37)
L8 48 S L7 AND (7-36)
L9 48 S L8 AND PH
L10 4 S L8 AND BASIC PH

=> s l9 and preservative

L11 12 L9 AND PRESERVATIVE

=> d l11 ti abs ibib tot

L11 ANSWER 1 OF 12 USPATFULL on STN

TI Inhibition of beta cell degeneration

AB This invention relates to a method for modulating, inhibiting or decreasing or preventing beta cell degeneration, loss of beta cell function, beta cell dysfunction, and/or death of beta cells, such as necrosis or apoptosis of beta cells in a subject comprising administering a GLP-1 agonist to said subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312646 USPATFULL

TITLE: Inhibition of beta cell degeneration

INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK
Godtfredsen, Carsten Foged, Herlev, DENMARK
Petersen, Jacob Sten, Copenhagen O, DENMARK
Carr, Richard David, Vaerloose, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003220251	A1	20031127
APPLICATION INFO.:	US 2003-372485	A1	20030224 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-709856, filed on 10 Nov 2000, GRANTED, Pat. No. US 6569832		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-1628	19991112
	DK 2000-270	20000222
	US 1999-166800P	19991122 (60)
	US 2000-185845P	20000229 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2373	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 12 USPATFULL on STN

TI Derivatives of GLP-1 analogs

AB The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:283328 USPATFULL

TITLE: Derivatives of GLP-1 analogs

INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK

Huusfeldt, Per Olaf, Kobenhavn K, DENMARK
Nielsen, Per Franklin, Vaerloose, DENMARK
Kaarsholm, Niels C., Vanlose, DENMARK
Olsen, Helle Birk, Allerod, DENMARK
Bjorn, Soren Erik, Lyngby, DENMARK
Pedersen, Freddy Zimmerdahl, Vaerloose, DENMARK
Madsen, Kjeld, Vaerloose, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199672	A1	20031023
APPLICATION INFO.:	US 2002-285079	A1	20020819 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-398111, filed on 16 Sep 1999, GRANTED, Pat. No. US 6458924		
	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, GRANTED, Pat. No. US 6384016		
	Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, GRANTED, Pat. No. US 6268343		
	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED		
	Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED		
	Continuation-in-part of Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401

NUMBER OF CLAIMS: 238
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 19138
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 12 USPATFULL on STN

TI Protein formulations

AB The present invention discloses a stable, soluble formulation comprising a medically useful peptide or protein, a hydrophobic **preservative**, and nicotinamide. Said storage-stable, soluble formulation is useful as a multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100072 USPATFULL

TITLE: Protein formulations

INVENTOR(S): Rinella, Vincent Joseph, JR., Brownsburg, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069182	A1	20030410
	US 6573237	B2	20030603
APPLICATION INFO.:	US 2002-170301	A1	20020612 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-787500, filed on 16 Mar 2001, GRANTED, Pat. No. US 6440930		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	700		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L11 ANSWER 4 OF 12 USPATFULL on STN
 TI Glucagon-like peptide-1 crystals
 AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL
 TITLE: Glucagon-like peptide-1 crystals
 INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED STATES
 Hoffmann, James Arthur, Greenwood, IN, UNITED STATES
 Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045464	A1	20030306
	US 6555521	B2	20030429
APPLICATION INFO.:	US 2001-997792	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-209799, filed on 11 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69728P	19971216 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1128	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L11 ANSWER 5 OF 12 USPATFULL on STN
 TI Use of glycogen phosphorylase inhibitors
 AB The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:4123 USPATFULL
TITLE: Use of glycogen phosphorylase inhibitors
INVENTOR(S): Treadway, Judith L., Mystic, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004162	A1	20030102
APPLICATION INFO.:	US 2001-813335	A1	20010320 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191381P	20000322 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159,, Eastern Point Road, Groton, CT, 06340	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4011	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 12 USPATFULL on STN

TI GLP-1 formulations

AB Methods and formulations are presented that provide for a) the oral absorption of GLP-1 peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a GLP-1/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other GLP-1 treated conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:228306 USPATFULL
TITLE: GLP-1 formulations
INVENTOR(S): Hoffmann, James Arthur, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002123466	A1	20020905
APPLICATION INFO.:	US 2002-72540	A1	20020208 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-573809, filed on 18 May 2000, GRANTED, Pat. No. US 6410513 Continuation of Ser. No. WO 1998-US25515, filed on 2 Dec 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67600P	19971205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	

LINE COUNT: 546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 12 USPATFULL on STN

TI Protein formulations

AB The present invention discloses a stable, soluble formulation comprising a medically useful peptide or protein, a hydrophobic preservative, and nicotinamide. Said storage-stable, soluble formulation is useful as a multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:217237 USPATFULL

TITLE: Protein formulations

INVENTOR(S): Rinella, Jr., Vincent Joseph, Brownsburg, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6440930	B1	20020827
	WO 2000015224		20000323
APPLICATION INFO.:	US 2001-787500		20010316 (9)
	WO 1999-US21055		19990914
			20010316 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-100687P	19980917 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Stewart, Mark J., Davis, Paula K.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	715	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 12 USPATFULL on STN

TI Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders

AB The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:67183 USPATFULL

TITLE: Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders

INVENTOR(S): Henriksen, Dennis Bang, Alleroed, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037836	A1	20020328
APPLICATION INFO.:	US 2001-954304	A1	20010918 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-22844	20000918

GB 2000-29920 20001207
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERI
YORK, NY, 100362711
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 2814
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 12 USPATFULL on STN

TI GLP-1 formulations

AB Methods and formulations are presented that provide for a) the oral absorption of GLP-1 peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a GLP-1/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other GLP-1 treated conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:57761 USPATFULL
TITLE: GLP-1 formulations
INVENTOR(S): Hoffmann, James Arthur, Greenwood, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358924	B1	20020319
APPLICATION INFO.:	US 2000 -585181		20000601 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1998-US25515, filed on 2 Dec 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67600P	19971205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Russel, Jeffrey E.	
LEGAL REPRESENTATIVE:	Stewart, Mark J., Cox, Gregory A.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	490	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 12 USPATFULL on STN

TI GLUCAGON-LIKE PEPTIDE-1 CRYSTALS

AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:134217 USPATFULL
TITLE: GLUCAGON-LIKE PEPTIDE-1 CRYSTALS
INVENTOR(S): HERMELING, RONALD NORBERT, INDIANAPOLIS, IN, United States
HOFFMANN, JAMES ARTHUR, GREENWOOD, IN, United States
NARASIMHAN, CHAKAVARTHY, CARMEL, IN, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014666	A1	20010816
	US 6380357	B2	20020430
APPLICATION INFO.:	US 1998-209799	A1	19981211 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBERT A CONRAD, ELI LILLY AND COMPANY, PATENT DIVISION/RSM, LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1106		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L11 ANSWER 11 OF 12 USPATFULL on STN

TI DERIVATIVES OF GLP-1 ANALOGS

AB The present invention relates to a pharmaceutical composition comprising
a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:123563 USPATFULL
TITLE: DERIVATIVES OF GLP-1 ANALOGS
INVENTOR(S): KNUDSEN, LISELOTTE BJERRE, VALBY, Denmark
HUUSFELDT, PER OLAF, KOBENHAVN K, Denmark
NIELSEN, PER FRANKLIN, VARLOSE, Denmark
KAARSHOLM, NIELS C., VANLOSE, Denmark
OLSEN, HELLE BIRK, ALLEROD, Denmark
BJORN, SOREN ERIK, LYNGBY, Denmark
PEDERSEN, FREDDY ZIMMERDAHL, VARLOSE, Denmark
MADSEN, KJELD, VARLOSE, Denmark

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011071	A1	20010802
	US 6458924	B2	20021001
APPLICATION INFO.:	US 1999-398111	A1	19990916 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED A 371 of International Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)
	US 1998-78422P	19980318 (60)

US 1998-82478P	19980421 (60)
US 1998-82479P	19980421 (60)
US 1998-82480P	19980421 (60)
US 1998-82802P	19980423 (60)
US 1998-84357P	19980505 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: STEVE T ZELSON, NOVO NORDISK OF NORTH AMERICA INC, 405 LEXINGTON AVENUE, SUITE 6400, NEW YORK, NY, 101746401
 NUMBER OF CLAIMS: 238
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Page(s)
 LINE COUNT: 15340
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 12 USPATFULL on STN

TI Derivatives of GLP-1 analogs
 AB The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:121450 USPATFULL
 TITLE: Derivatives of GLP-1 analogs
 INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, Denmark
 Huusfeldt, Per Olaf, K.o slashed.benhavn K, Denmark
 Nielsen, Per Franklin, V.ae butted.rl.o slashed.se, Denmark
 Kaarsholm, Niels C., Vanl.o slashed.se, Denmark
 Olsen, Helle Birk, Aller.o slashed.d, Denmark
 Bj.o slashed.rn, S.o slashed.ren Erik, Lyngby, Denmark
 Pedersen, Freddy Zimmerdahl, V.ae butted.rl.o slashed.se, Denmark
 Madsen, Kjeld, V.ae butted.rl.o slashed.se, Denmark
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6268343	B1	20010731
APPLICATION INFO.:	US 1999-258750		19990226 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, now abandoned Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, now abandoned Continuation-in-part of Ser. No. WO 1997-DK340, filed on 22 Aug 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Borin, Michael

LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Lambiris, Esq., Elias J.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 14165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT
17:28:55 ON 30 JAN 2004

L1 7447 S GLP-1
L2 514 S L1 AND ANALOG
L3 61 S L2 AND (7-34)
L4 1 S L3 AND TONICITY MODIFIER
L5 61 S L3 AND SOLUTION
L6 52 S L5 AND (7-35)
L7 48 S L6 AND (7-37)
L8 48 S L7 AND (7-36)
L9 48 S L8 AND PH
L10 4 S L8 AND BASIC PH
L11 12 S L9 AND PRESERVATIVE

=> s l9 and TRIS

L12 31 L9 AND TRIS

=> s l12 and BRIJ-35

L13 2 L12 AND BRIJ-35

=> d l13 ti abs ibib tot

L13 ANSWER 1 OF 2 USPATFULL on STN

TI Derivatives of GLP-1 analogs

AB The present invention relates to a pharmaceutical composition comprising
a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:283328 USPATFULL

TITLE: Derivatives of GLP-1 analogs

INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK

Huusfeldt, Per Olaf, Kobenhavn K, DENMARK

Nielsen, Per Franklin, Vaerlose, DENMARK

Kaarsholm, Niels C., Vanlose, DENMARK

Olsen, Helle Birk, Allerod, DENMARK

Bjorn, Soren Erik, Lyngby, DENMARK

Pedersen, Freddy Zimmerdahl, Vaerlose, DENMARK

Madsen, Kjeld, Vaerlose, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199672	A1	20031023
APPLICATION INFO.:	US 2002-285079	A1	20020819 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-398111, filed on 16 Sep 1999, GRANTED, Pat. No. US 6458924		
	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, GRANTED, Pat. No. US 6384016		
	Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, GRANTED, Pat. No. US 6268343		
	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED		
	Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED		

Continuation-in-part of Ser. No. WO 1997-DK340, filed
on 22 Aug 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401	
NUMBER OF CLAIMS:	238	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	19138	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L13 ANSWER 2 OF 2 USPATFULL on STN

TI DERIVATIVES OF GLP-1 ANALOGS

AB The present invention relates to a pharmaceutical composition comprising
a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:123563 USPATFULL
TITLE: DERIVATIVES OF GLP-1 ANALOGS
INVENTOR(S): KNUDSEN, LISELOTTE BJERRE, VALBY, Denmark
HUUSFELDT, PER OLAF, KOBENHAVN K, Denmark
NIELSEN, PER FRANKLIN, VARLOSE, Denmark
KAARSHOLM, NIELS C., VANLOSE, Denmark
OLSEN, HELLE BIRK, ALLEROD, Denmark
BJORN, SOREN ERIK, LYNGBY, Denmark
PEDERSEN, FREDDY ZIMMERDAHL, VARLOSE, Denmark
MADSEN, KJELD, VARLOSE, Denmark

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011071	A1	20010802
	US 6458924	B2	20021001
APPLICATION INFO.:	US 1999-398111	A1	19990916 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED A 371 of International Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

NUMBER	DATE

PRIORITY INFORMATION: DK 1996-931 19960830
 DK 1996-1259 19961108
 DK 1996-1470 19961220
 DK 1998-263 19980227
 DK 1998-264 19980227
 DK 1998-268 19980227
 EP 1998-610006 19980313
 DK 1998-507 19980408
 DK 1998-272 19980227
 DK 1998-274 19980227
 DK 1998-508 19980408
 DK 1998-509 19980408
 US 1997-35904P 19970124 (60)
 US 1997-36226P 19970125 (60)
 US 1997-36255P 19970124 (60)
 US 1998-78422P 19980318 (60)
 US 1998-82478P 19980421 (60)
 US 1998-82479P 19980421 (60)
 US 1998-82480P 19980421 (60)
 US 1998-82802P 19980423 (60)
 US 1998-84357P 19980505 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: STEVE T ZELSON, NOVO NORDISK OF NORTH AMERICA INC, 405
 LEXINGTON AVENUE, SUITE 6400, NEW YORK, NY, 101746401
 NUMBER OF CLAIMS: 238
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Page(s)
 LINE COUNT: 15340
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT
 17:28:55 ON 30 JAN 2004

L1 7447 S GLP-1
 L2 514 S L1 AND ANALOG
 L3 61 S L2 AND (7-34)
 L4 1 S L3 AND TONICITY MODIFIER
 L5 61 S L3 AND SOLUTION
 L6 52 S L5 AND (7-35)
 L7 48 S L6 AND (7-37)
 L8 48 S L7 AND (7-36)
 L9 48 S L8 AND PH
 L10 4 S L8 AND BASIC PH
 L11 12 S L9 AND PRESERVATIVE
 L12 31 S L9 AND TRIS
 L13 2 S L12 AND BRIJ-35

=> d l12 ti abs ibib 1-15

L12 ANSWER 1 OF 31 USPATFULL on STN
 TI Novel glucagon antagonists/inverse agonists
 AB Novel compounds that act to antagonize the action of the glucagon
 peptide hormone on the glucagon receptor. More particularly, it relates
 to glucagon antagonists or inverse agonists.

ACCESSION NUMBER: 2004:19485 USPATFULL
 TITLE: Novel glucagon antagonists/inverse agonists
 INVENTOR(S): Lau, Jesper, Farum, DENMARK
 Christensen, Inge Thoger, Lyngby, DENMARK

Madsen, Peter, Bagsvaerd, DENMARK
Bloch, Paw, Taastrup, DENMARK
Behrens, Carsten, Kobenhavn, DENMARK
Kodra, Janos Tibor, Kobenhavn, DENMARK
Nielsen, Poul Enrico, Borup, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014789	A1	20040122
APPLICATION INFO.:	US 2003-448529	A1	20030530 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-1789	20011203
	DK 2002-1006	20020627
	DK 2002-1927	20021217
	US 2002-394145P	20020703 (60)
	US 2002-434255P	20021218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc.,
100 College Road West, Princeton, NJ, 08540
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
LINE COUNT: 4435

L12 ANSWER 2 OF 31 USPATFULL on STN

TI Modified transferrin fusion proteins
AB Modified fusion proteins of transferrin and therapeutic proteins or
peptides including soluble toxin receptors, with increased serum
half-life or serum stability are disclosed. Preferred fusion proteins
include those modified so that the transferrin moiety exhibits no or
reduced glycosylation, binding to iron and/or binding to the transferrin
receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:313593 USPATFULL
TITLE: Modified transferrin fusion proteins
INVENTOR(S): Prior, Christopher P., King of Prussia, PA, UNITED STATES
Lai, Char-Huei, King of Prussia, PA, UNITED STATES
Sadeghi, Homayoun, King of Prussia, PA, UNITED STATES
Turner, Andrew, King of Prussia, PA, UNITED STATES
PATENT ASSIGNEE(S): BIOREXIS PHARMACEUTICAL CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003221201	A1	20031127
APPLICATION INFO.:	US 2003-378094	A1	20030304 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-231494, filed on 30 Aug 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-315745P	20010830 (60)
	US 2001-334059P	20011130 (60)
	US 2002-406977P	20020830 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	

LINE COUNT: 5075
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 31 USPATFULL on STN

TI Glucagon antagonists/inverse agonists

AB A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312745 USPATFULL

TITLE: Glucagon antagonists/inverse agonists

INVENTOR(S): Lau, Jesper, Farum, DENMARK
Madsen, Peter, Bagsvaerd, DENMARK
Sams, Christian, Frederiksberg, DENMARK
Behrens, Carsten, Copenhagen N, DENMARK
Vagner, Josef, Oro Valley, AZ, UNITED STATES
Christensen, Inge Thoger, Lyngby, DENMARK
Lundt, Behrend Frederik, Kokkedal, DENMARK
Sidelmann, Ulla Grove, Vedbaek, DENMARK
Thogersen, Henning, Farum, DENMARK
Ling, Anthony L., San Diego, CA, UNITED STATES
Plewe, Michael Bruno, San Diego, CA, UNITED STATES
Truesdale, Larry Kenneth, San Diego, CA, UNITED STATES
Jogensen, Anker Steen, Copenhagen, DENMARK
Kodra, Janos Tibor, Copenhagen, DENMARK
Shi, Shenghua, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003220350	A1	20031127
APPLICATION INFO.:	US 2002-233851	A1	20020830 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-572553, filed on 16 May 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-684	19990517
	DK 2000-478	20000321
	US 1999-134415P	19990517 (60)
	US 2000-191685P	20000323 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington, New York, NY, 10174-6400

NUMBER OF CLAIMS: 88

EXEMPLARY CLAIM: 1

LINE COUNT: 13924

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 31 USPATFULL on STN

TI Derivatives of GLP-1 analogs

AB The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:283328 USPATFULL

TITLE: Derivatives of GLP-1 analogs

INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK
Huusfeldt, Per Olaf, Kobenhavn K, DENMARK
Nielsen, Per Franklin, Vaerlose, DENMARK

Kaarsholm, Niels C., Vanlose, DENMARK
 Olsen, Helle Birk, Allerod, DENMARK
 Bjorn, Soren Erik, Lyngby, DENMARK
 Pedersen, Freddy Zimmerdahl, Vaerlose, DENMARK
 Madsen, Kjeld, Vaerlose, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199672	A1	20031023
APPLICATION INFO.:	US 2002-285079	A1	20020819 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-398111, filed on 16 Sep 1999, GRANTED, Pat. No. US 6458924		
	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, GRANTED, Pat. No. US 6384016		
	Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, GRANTED, Pat. No. US 6268343		
	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED		
	Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED		
	Continuation-in-part of Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401	
NUMBER OF CLAIMS:	238	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	19138	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 5 OF 31 USPATFULL on STN

TI Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins

AB The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:277127 USPATFULL
 TITLE: Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
 INVENTOR(S): Walker, Kenneth, Newbury Park, CA, UNITED STATES
 Xiong, Fei, Thousand Oaks, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003195154	A1	20031016
APPLICATION INFO.:	US 2003-407078	A1	20030403 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-117109, filed on 4 Apr 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Page(s)		
LINE COUNT:	3042		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L12 ANSWER 6 OF 31 USPATFULL on STN
 TI Crystallisation of a GLP-1 analogue
 AB Crystals of glucagon-like peptide-1 (GLP-1) and GLP-1 analogues, and processes for preparation of crystals of GLP-1 and GLP-1 analogues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 2003:265841 USPATFULL
 TITLE: Crystallisation of a GLP-1 analogue
 INVENTOR(S): Arentsen, Anne Charlotte, Holte, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186858	A1	20031002
APPLICATION INFO.:	US 2001-769692	A1	20010125 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	NL 2000-156	20000131
	US 2000-183300P	20000217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6400	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1159	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 7 OF 31 USPATFULL on STN
 TI C-aryl glucoside SGLT2 inhibitors and method
 AB A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula ##STR1##

alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:166532 USPATFULL
TITLE: C-aryl glucoside SGLT2 inhibitors and method
INVENTOR(S): Washburn, William N., Titusville, NJ, UNITED STATES
Ellsworth, Bruce, Princeton, NJ, UNITED STATES
Meng, Wei, Pennington, NJ, UNITED STATES
Wu, Gang, Princeton, NJ, UNITED STATES
Sher, Philip M., Plainsboro, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003114390	A1	20030619
APPLICATION INFO.:	US 2002-264410	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-805341, filed on 13 Mar 2001, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2410		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 31 USPATFULL on STN

TI Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
AB The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:153409 USPATFULL
TITLE: Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
INVENTOR(S): Kanstrup, Anders Bendtz, Espergaerde, DENMARK
Sams, Christian Klarner, Frederiksberg C, DENMARK
Lundbeck, Jane Marie, Glostrup, DENMARK
Christiansen, Lise Brown, Lyngby, DENMARK
Kristiansen, Marit, Soborg, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003105077	A1	20030605
APPLICATION INFO.:	US 2002-186498	A1	20020628 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-1049	20010703
	DK 2002-180	20020206
	US 2001-309621P	20010802 (60)
	US 2002-356631P	20020208 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq.,, Novo Nordisk of North America, Inc.,, Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2972	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 31 USPATFULL on STN

TI Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:141004 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
Jeon, Yoon, Belle Mead, NJ, UNITED STATES
Chen, Sean, Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096846	A1	20030522
	US 6653314	B2	20031125
APPLICATION INFO.:	US 2002-80981	A1	20020222 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-812960, filed on 20 Mar 2001, GRANTED, Pat. No. US 6414002 Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5718	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 31 USPATFULL on STN

TI Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:127720 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
Jeon, Yoon, Belle Mead, NJ, UNITED STATES
Chen, Sean, Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087935	A1	20030508

APPLICATION INFO.: US 2002-81075 A1 20020222 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 2001-812960, filed on 20 Mar
2001, PENDING Continuation-in-part of Ser. No. US
2000-664598, filed on 18 Sep 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5712	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 31 USPATFULL on STN
TI Indole carboxylic acids as thyroid receptor ligands
AB A compound of the formula ##STR1##

wherein W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6,
R.sup.7, R.sup.8 and R.sup.13 are as defined herein, useful in the
treatment of obesity, overweight condition, hyperlipidemia, glaucoma,
cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism,
thyroid cancer and related disorders and diseases such as diabetes
mellitus, atherosclerosis, hypertension, coronary heart disease,
congestive heart failure, hypercholesteremia, depression, osteoporosis
and hair loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:113548 USPATFULL
TITLE: Indole carboxylic acids as thyroid receptor ligands
INVENTOR(S): Aspnes, Gary E., Rockville, RI, UNITED STATES
Chiang, Yuan-Ching P., East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078289	A1	20030424
APPLICATION INFO.:	US 2002-255180	A1	20020924 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-325385P	20010926 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3688	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 31 USPATFULL on STN
TI Combination of FBPase inhibitors and antidiabetic agents useful for the
treatment of diabetes
AB A combination therapy of at least one FBPase inhibitor and at least one
other antidiabetic agent is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:106816 USPATFULL
TITLE: Combination of FBPase inhibitors and antidiabetic
agents useful for the treatment of diabetes
INVENTOR(S): van Poelje, Paul D., La Jolla, CA, UNITED STATES

Erion, Mark D., Del Mar, CA, UNITED STATES
Fujiwara, Toshihiko, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073728	A1	20030417
APPLICATION INFO.:	US 2001-900364	A1	20010705 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-216531P	20000706 (60)
	US 2000-215126P	20000629 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BROBECK, PHLEGER & HARRISON LLP, 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130	
NUMBER OF CLAIMS:	114	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	12671	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 13 OF 31 USPATFULL on STN

TI Substituted acid derivatives useful as antidiabetic and antiobesity
agents and method

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and
R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n
are as defined herein, which compounds are useful as antidiabetic,
hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100164 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and
antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES
Jeon, Yoon, Belle Mead, NJ, UNITED STATES
Chen, Sean, Princeton, NJ, UNITED STATES
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069275	A1	20030410
APPLICATION INFO.:	US 2002-80965	A1	20020222 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5710	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 14 OF 31 USPATFULL on STN

TI Protein formulations

AB The present invention discloses a stable, soluble formulation comprising a medically useful peptide or protein, a hydrophobic preservative, and nicotinamide. Said storage-stable, soluble formulation is useful as a multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100072 USPATFULL
TITLE: Protein formulations
INVENTOR(S): Rinella, Vincent Joseph, JR., Brownsburg, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069182	A1	20030410
	US 6573237	B2	20030603
APPLICATION INFO.:	US 2002-170301	A1	20020612 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-787500, filed on 16 Mar 2001, GRANTED, Pat. No. US 6440930		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	700		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 15 OF 31 USPATFULL on STN

TI Glucagon-like peptide-1 crystals

AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL
TITLE: Glucagon-like peptide-1 crystals
INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED STATES
Hoffmann, James Arthur, Greenwood, IN, UNITED STATES
Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045464	A1	20030306
	US 6555521	B2	20030429
APPLICATION INFO.:	US 2001-997792	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-209799, filed on 11 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69728P	19971216 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1128	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Refine Search

Search Results -

Terms	Documents
6358924.pn.	1

Database:

- US Pre-Grant Publication Full-Text Database
- US Patents Full-Text Database
- US OCR Full-Text Database
- EPO Abstracts Database
- JPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Search:

L4

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Friday, January 30, 2004 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set

DB=USPT; PLUR=YES; OP=OR

<u>L4</u>	6358924.pn.	1	<u>L4</u>
<u>L3</u>	6573237.pn.	1	<u>L3</u>
<u>L2</u>	6268343.pn.	1	<u>L2</u>
<u>L1</u>	6458924.pn.	1	<u>L1</u>

END OF SEARCH HISTORY